Rosuvastatin

Research use only, not for human use.

A potent, competitive inhibitor of HMG-CoA reductase (HMGCR) with IC50 of 11 nM.

A potent, competitive inhibitor of HMG-CoA reductase (HMGCR) with IC50 of 11 nM; potently inhibits cholesterol biosynthesis (IC50=1.12 nM) in rat isolated hepatocytes, 100 times more potent than pravastatin; also exerts important anti-inflammatory effects via inhibition of endothelial cell adhesion molecule expression.Dyslipidemia Approved(In Vivo):Rosuvastatin Calcium (10 mg/kg, intraperitoneal) prolonges QTc in conscious and unrestraines guinea pigs from 201±1 to 210±2 ms.Rosuvastatin (20 mg/kg/day, for 2 weeks) significantly reduces very low-density lipoproteins Calcium (VLDL) in diabetes mellitus rats induced by Streptozocin.

——

Rosuvastatin (10 mg/kg, intraperitoneal) prolonges QTc in conscious and unrestraines guinea pigs from 201±1 to 210±2 ms. Rosuvastatin (20 mg/kg/day, for 2 weeks) significantly reduces very low-density lipoproteins (VLDL) in diabetes mellitus rats induced by Streptozocin.

ZD-4522

Metabolic Enzyme/Protease

HMGCR

HMG-CoAreductase

Cardiovascular Disease

Dyslipidemia

287714-41-4

481.5376

C22H28FN3O6S

>98% (HPLC)

10 mM in DMSO

CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C

6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-

(-20℃)

With Ice Pack

≥ 2 years